ReviewDrug design, development and therapy2026
Bicaudal‑C1 in Cancer: Molecular Mechanisms and Therapeutic Strategies Integrating Chinese and Western Medicine.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bicaudal-C homolog 1 (BICC1) is an essential RNA-binding protein that plays a significant role in cellular signaling and gene expression regulation. Recent research has linked the BICC1 gene to the initiation and advancement of tumors. Current investigations primarily aim to elucidate its structural characteristics and functional roles, while its precise involvement in tumorigenesis and its viability as a therapeutic target are still being explored. This review delves into the structure and functions of BICC1, emphasizing its participation in tumor cell growth, programmed cell death, epithelial-mesenchymal transition (EMT), blood vessel formation, maintenance of stem cells, and chemoresistance. Furthermore, it examines progress in developing drugs that target BICC1 for cancer therapy and evaluates the potential advantages of traditional Chinese medicine in mediating anti-tumor effects through BICC1 modulation, offering perspectives for future targeted treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.